Abstract. Glycation and nitrotyrosination are pathological posttranslational modifications that make proteins prone to losing their physiological properties. Since both modifications are increased in Alzheimer's disease (AD) due to amyloid β-peptide (Aβ) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood.
INTRODUCTION
Alzheimer's disease (AD) is characterized by amyloid β-peptide (Aβ) aggregates forming senile plaques in the brain parenchyma [1] and vascular amyloid deposits in brain vessels [2] . Aβ aggregation produce oligomers and fibrils [3, 4] that generate reactive oxygen species (ROS) [5] . These ROS due to their gaseous nature can diffuse into the surrounding tissues to neuron and vessels where its deleterious effects are amplified by the intracellular free radical cascades. In the downstream of the cellular Aβ effects there is a high production of superoxide anion from mitochondria that reacts with nitric oxide (NO), mainly produced by glial and endothelial cells but also by neurons [6, 7, 8] , to render peroxynitrite (ONOO -) [9] . This peroxynitrite nitrates the tyrosine residues in proteins, a process termed nitrotyrosination, which dramatically affects their function [10, 11] . Consistently protein nitrotyrosination has previously been detected in brain proteins in AD patients [12, 13, 14] and free 3-nitrotyrosine (NT-3) in serum from AD patients [15] .
The intracellular effects of Aβ also includes high methylglyoxal (MG) production from abnormal glycolysis [16] . MG reacts with proteins to glycate them but protein glycation can be also indirectly produced in a pro-oxidant environment by advanced glycation end products through the Maillard reaction, in both cases facilitating the pathological crosslink 4 between glycated proteins [17] . Consequently high protein glycation has been reported in AD brains [18, 19, 20] .
Albumin is the most abundant protein in both blood and cerebrospinal fluid (CSF).
Plasmatic albumin is produced by the liver and a small fraction of plasmatic albumin enters the brain [21] although most of the albumin found there is produced endogenously by the glia [22] . The functions of albumin are the regulation of blood and CSF volume by maintaining the oncotic pressure, and the transport of different molecules like hormones, free fatty acids, ions and some drugs. Albumin can also buffer oxidative damage due to the presence of a free cysteine that is not forming disulfide bridges [23] . Interestingly, albumin has been previously reported to bind Aβ [24] that could be favoring amyloidogenic clearance by the liver. In addition, albumin has a potential role as a molecular chaperone, preventing the misfolding and aggregation of proteins [25] and specifically inhibiting Aβ fibril formation [26] .
Albumin has 19 tyrosines susceptible to modification by peroxynitrite [27] as well as a high number of lysines and arginines, which are also quite prone to glycation [28] .
Therefore albumin can be affected by the increased nitro-glycative stress present in AD. This study analyses the albumin modifications caused by nitro-glycative stress and their effects in its functions, its impact on different cell types present at both sides of the blood brain barrier (BBB) and the effect in the inhibition of Aβ aggregation.
MATERIALS AND METHODS

Cell lines
Human umbilical vein endothelial cell line (HUVEC) was cultured in M-199 medium supplemented with 10% fetal bovine serum (FBS; Sigma), 2 mM of L-Glutamine (Sigma), 100 UI/mL of penicillin and 100 µg/mL of streptomycin (Sigma 
Human CSF samples
A total of 20 CSF samples obtained at the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) were included in this study. The procedure was approved by the ethics committee of the Hospital de la Santa Creu i Sant Pau. CSF samples were from 10 cognitively normal controls (66.9 ± 2.2 years) and from 10 AD patients (66.6 ± 2.5 years) using previously described procedures [29] . 
Albumin nitrotyrosination and glycation
Unless indicated otherwise, 1.25 µg/µL of human albumin (Grifols) was incubated with increasing concentrations (100 µM to 50 mM) of the peroxynitrite donor 3-Morpholinosydnonimine hydrochloride (SIN-1; Sigma) and the glycating agent MG (CosmoBio Co., LTD) in a phosphate buffer solution (PBS). The solutions were stirred (300 rpm) for 3 hr at room temperature (RT). After treatment, the albumin was filtrated by centrifugation at 11,000 rpm for 10 min in 30 KDa desalting filters (Vivacon 500 and Ultrafree-MC microcentrifuge filters, Sigma). Protein was recovered by revert spinning at 2,500 rpm for 2.5 min and quantified using the BCA. 
Albumin immunoprecipitation (IP)
100
Albumin degradation by trypsin
Native, glyco-and nitro-Albumin (G-Alb and N-Alb) were incubated with 0.05%
Trypsin-EDTA (Gibco BRL, Invitrogen) for 24 hr. A soy trypsin inhibitor (STI; Sigma) was used at 1 mg/mL to stop trypsin activity. Albumin samples were resolved in 8% non denaturating polyacrylamide gels. Protein detection used Coomassie protein staining techniques.
Albumin uptake by HepG2 cells
HepG2 cells were seeded in 6-well plates at a density of 7. 
RESULTS
Albumin is glycated and nitrotyrosinated in brain and plasma samples from AD patients
The presence of N-Alb and G-Alb in the CSF, plasma and brains of AD patients and aged non-demented controls is shown in Fig. 1 . The studies of albumin glycation were performed with an argpyrimidine Ab since argpyrimidine is a main modification in albumin glycated by MG [31] . We found similar percentages of albumin glycation in the CSF of AD patients and controls (84.5±12.5) but significantly higher in brain and plasma (150.6±19.3
and 120.5±8.7 respectively; p<0.05 in both cases; Fig. 1A ). Albumin nitrotyrosination also
presented similar values in CSF from controls and AD patients (100±32.9 and 62.1±7.6 respectively) but significantly higher in brain and plasma from AD patients (134.9±15.1 and 141±12.8 respectively; p<0.05 and p<0.01; Fig. 1B ).
Albumin nitrotyrosination in CSF from AD patients correlates with Aβ 1-42 levels
The levels of Aβ , tau and p-tau were analyzed in CSF samples from cognitively normal subjects and AD patients (Fig. 2, S1 and S2). We found that there was no correlation between the levels of Aβ 1-42 and glycated or nitrated albumin when total samples or just controls were analyzed ( Fig. 2A-D) . Interestingly, there was a high negative correlation between Aβ 1-42 levels and nitrated albumin in the CSF from AD patients (r=-097; p<0.005; Fig. 2F ). This correlation was not found for glycated albumin (Fig. 2E) .
The statistical analysis between tau and p-tau levels and glycated and nitrotyrosinated albumin ( Fig. S1 and S2 ) did not show any correlation except for tau levels compared to nitrotyrosinated albumin in AD patients (Fig. S1F) , where a positive correlation was obtained (r=0.63; p<0.05).
Glycation and nitrotyrosination induce albumin aggregation in vitro
The ability of albumin to be glycated by MG, a glycating agent, and nitrated by SIN-1, a peroxynitrite donor, measured by western blot (WB) analysis, is shown in Fig. S3 .
Albumin glycation is augmented with increasing MG concentration up to 7.5 mM whereas higher doses of MG triggered an apparent decrease of albumin glycation (Fig. S3A) . This effect at concentrations above 7.5 mM MG could be due to cross-linking of glycated albumin to form large aggregates unable to enter the polyacrylamide gels and, therefore, not be detected at the molecular weight of monomeric albumin. The glycation of albumin at lower µM concentrations is shown in the inset in Fig. S3A . Albumin nitration however is augmented with increasing doses of SIN-1 up to 12.5 mM when reached a plateau. A SIN-1 concentration of more than 12.5 mM did not produce greater nitration probably due to complete nitration of all the tyrosine at this concentration (Fig. S3B ).
Micromolar concentrations of MG and peroxynitrite are found in plasma [32, 33] , although their tissue concentrations are claimed to be higher. We have carried out the experiments of the present work at 25 mM MG and 12.5 or 25 mM SIN-1 since the production of both harmful compounds is constant in AD and the long turnover of albumin (21 days) [34] makes this protein to be highly exposed to these compounds.
Glycation and nitrotyrosination have been previously reported to induce protein aggregation. Turbidimetric assays consistently showed aggregation of G-Alb and N-Alb compared to untreated albumin ( Fig. 3A and B) . The aggregation of N-Alb showed higher turbidimetry absorbance values than G-Alb. Not only are the aggregation kinetics between nitrated and glycated albumin different, but the appearance of the aggregates differ as well.
Structural differences between untreated and glycated or nitrotyrosinated albumin aggregates were evident under AFM after 3 days of treatment ( Fig. 3C and D) . At that time the small 14 fibrillar forms of the untreated albumin have mostly disappeared in the glycated and nitrotyrosinated albumin, remaining amorphous aggregates bound to the graphite matrix.
These amorphous aggregates grow along the time as we found by electron microscopy after 4 weeks of treatment ( Fig. 3E and F) . G-Alb aggregates showed globular structures different to those present in untreated or nitrated albumin aggregates. The turbidimetry pattern observed for G-Alb could be due to the formation of larger and more expanded aggregates as this would explain the results obtained by WB (Fig. S3 ) and electron microscopy. In addition, NAlb aggregates were more condensed that untreated and glycated albumin aggregates
Trypsin digestion and cell uptake of N-Alb and G-Alb
Albumin turnover, taking approximately 21 days in humans [34] involves its degradation and uptake by liver cells, a process that may be affected by its nitration and glycation, how it was reported for MG-modified bovine serum albumin in proximal tubule epithelial cell [35] . The impairment of albumin digestion and/or uptake will mean a reduction of albumin production by the liver, and consequently it will affect the physiological functions of albumin. To address this point, an evaluation was made of the digestion of modified and native albumin. Untreated, N-Alb and G-Alb samples incubated with trypsin are shown in Fig. 4A . As expected, higher degradation (fragments <50 kD molecular weight) was observed in untreated albumin compared to N-Alb and G-Alb. Digestion of N-Alb produced less low molecular weight fragments. G-Alb was the most resistant to trypsin digestion. Next, an assessment was made of the cellular uptake of modified and native albumin by hepatoma cells (Fig. 4B) . In cells incubated with native albumin, G-Alb and N-Alb in a serum-free medium, there was a significant reduction of G-Alb uptake (0.41 ± 0.33 µg/µL; p<0.05) by cells compared to untreated albumin (6.89 ± 3.31 µg/µL) whereas nitrotyrosinated albumin uptake was not affected (6.04 ± 4.03 µg/µL).
Albumin glycation reduces osmolarity
Since nitrotyrosination and glycation produce albumin aggregates, these modifications were studied to determine whether they could also be affecting osmotic pressure by enhancing the binding of ions from the solution. It was previously reported that MG-modified bovine serum albumin had a higher affinity for Cu 2+ and Ca
2+
compared to the native [36] .
Measurements were made of the osmolarity of solutions containing the same concentrations of untreated albumin, G-Alb and N-Alb (Fig. 5) . Nitrotyrosination of albumin with SIN-1 did not affect osmolarity (Fig. 5B ) whereas albumin glycation with increasing concentrations of MG ( Fig. 5A ) showed significant (p<0.05) reduction in osmolarity compared to control albumin. Since both modifications are coexisting in the same albumin pool, these data support that the pathophysiological effects of albumin modification on osmolarity control would be just due to albumin glycation. This reduction in osmolarity is probably due to trapping of the ions dissolved in the medium.
Effect of albumin nitrotyrosination and glycation on cell viability
Albumin interacts directly with the neurons, endothelium, vascular smooth muscle and glial cells at both sides of the BBB [21, 37, 38, 39] . The effect of albumin glycation and nitration on cell viability was tested using endothelial (HUVEC), vascular smooth muscle 
Increased Aβ binding to G-Alb and N-Alb
The results of Aβ binding experiments carried out with soluble and fibrillar Aβ are shown in Fig. 7 . The binding assay showed that G-Alb (Fig. 7A) and N-Alb (Fig. 7B ) bind more Aβ in soluble form than control albumin (p<0.005; p<0.05). Furthermore, G-Alb (Fig. 7B right panel) binds more Aβ in aggregated form than control albumin (p<0.05).
Albumin glycation and nitration impairs the inhibitory effect of albumin on Aβ 40 aggregation
Plasmatic albumin binds Aβ [40] and can inhibit its aggregation to form amyloid fibrils [28] . We have assayed the ability of native, glycated and nitrated albumin to inhibit Aβ 1-40 aggregation. Our results showed that albumin was able to abolish completely Aβ aggregation ( Fig. 8A, B ; quantified in Fig. S2 ), as previously reported by [28] , but both GAlb (Fig. 8A ) and N-Alb ( 
DISCUSSION
High nitro-oxidative stress is associated with the AD brain [5, 41, 42, 43] and this could affect the proteins at both sides of the BBB because of the gaseous nature of ROS, the chain reactions induced by these species in surrounding tissues and the ultrafiltration of proteins from CSF to blood. Albumin is the most abundant protein in both blood and CSF, in addition to its physiological functions, albumin may also play a major role as a scavenger of ROS, favored by its high turnover with a life of 21 days [34] . This process involves its degradation and uptake by liver cells and may be affected by albumin nitration and glycation. However, this ability might have consequences for albumin when the buffering threshold for oxidative stress is exceeded, as occurs in AD. This study focused on albumin nitrotyrosination and glycation, and how these modifications affect its properties. We found that albumin is significantly glycated and nitratred in brain and plasma from AD patients. Similar results regarding G-Alb have been published by Byun et al. [44] . In AD patients N-Alb from CSF correlates inversely with A 1-42 levels and positively with tau levels. It can be due to the A 1-42 aggregation in the brain parenchyma of AD patients, and the consequent neuronal damage produces tau release. The puzzling lack of differences in N-Alb levels in CSF between controls and AD patients can be the result of the rapid intracerebral aggregation of newly nitrated albumin impairing its ultrafiltration to CSF.
Both nitrotyrosination and glycation make albumin more prone to aggregation. In the case of nitrotyrosination, the interaction of nitrated tyrosines from several molecules of albumin-producing dityrosine bridges could lead to its aggregation [45] . Albumin glycation could also induce aggregation probably due to cross-linking between ketone groups from Schiff bases, the intermediate products after protein glycation [46] . In fact the apparent decrease at concentrations higher than 7.5 mM MG could be due to the cross-linking of glycated albumin forming large aggregates unable to enter the polyacrylamide gels and, therefore, not being detected at the molecular weight of monomeric albumin. Consequently an increased aggregation was obtained in the turbidimetric assay without reaching a plateau.
The changes in modified albumin observed under the transmission electron microscopy showed denser aggregates in nitrotyrosinated albumin and more globular aggregates in glycated albumin than those observed in unaltered albumin. These results are consistent with increased albumin aggregation.
The data suggest that these stable aggregates of modified albumin are not easily broken down, and therefore additional, accessory proteins may be required for their 18 degradation [47, 48] . G-Alb was the most resistant to trypsin digestion, and this is consistent with previous reports showing that protein glycation reduces their normal degradation [49, 50] . Besides, as proteolysis of large aggregates is more difficult, modified albumin will be circulating for longer periods of time, affecting its turnover and reducing its protective role. Another consequence of albumin modification affects maintenance of osmotic pressure.
Compared to native albumin, the presence of glycated, but not nitrotyrosinated albumin, significantly decreases the osmolarity of the solution it is dissolved in. The osmolarity is one of the most-well regulated physiological mechanism [51] and changes around 10% in the osmolarity might have deleterious consequences, especially for small brain vessels where it will favor plasma extravasation [52] and a lack in the homeostasis of the sorrounding tissue.
We also found that G-Alb decrease the viability of vascular myocytes and neuronal cells. N-Alb affects mainly endothelium and smooth muscle cells, while astrocytes seem to better tolerate the presence of modified albumin. This difference may indicate that a particular albumin modification will mainly affect a particular set of cell types. Since both nitrative and glycative modifications are additive in vivo, their deleterious effects would affect to all the surrounding cells in brain. Another interesting observation is that albumin may act as a buffer for the nitro-oxidative and glycative stress since the presence of albumin reduced the toxic effect of equimolar concentrations of free SIN-1 and MG ( Fig. S4 and S5 ).
The reduction in cell viability could be due to a lack of the nutritive properties of albumin [53] or other mechanisms derived from its aggregated structure. Interestingly, nitrating and glycating agents ( Fig. S4 and S5 ) are always more toxic to cells than the corresponding concentration of modified albumin, reinforcing the idea that albumin protects against these reactive species by buffering them [54] . Altogether, modified albumin could not buffer more pro-oxidant challenges in brain, and consequently, also could fail in protecting the brain against nitro-oxidative stress.
On the other hand, 95% of the plasmatic Aβ is bound to albumin [24, 40] allowing the hepatic clearance of Aβ-albumin complex. We have found that the modified albumin binds more soluble and aggregated Aβ than the native albumin. Albumin is known to inhibit Aβ aggregation [55] . It traps Aβ likely by hydrophobic interactions since it has hydrophobic pockets [56] . We speculate that glycation and nitration are decreasing the albumin inhibitory effect on Aβ aggregation due to the higher amount of Aβ bound after the modification of its structure. A similar mechanism has been proposed for the prions, which bind Aβ monomers and oligomers depending on its conformational estate [57, 58] . Once the load of Aβ is overcome, the high amount of monomers can interact to fibrillate. An excessive binding to 
